Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
February 29, 2024 16:05 ET
|
Y-mAbs Therapeutics, Inc.
Record DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash equivalents of $78.6 million as of December...
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
February 16, 2024 07:30 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full...
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
December 13, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
November 13, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
Q3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59%U.S. FDA clearance of IND for CD38-SADA for relapsed or refractory non-Hodgkin LymphomaCash and cash equivalents of...
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
October 31, 2023 07:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended...
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
October 18, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
October 17, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Publication in Cancers
October 16, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
September 21, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...